Novartis has seen a mix of headlines ranging from
positive growth signals,
noteworthy investments, and potential
areas of concern. Recent breakthroughs, such as the FDA approval of
Ianalumab, fueled a 1% rise in stocks and show a strong outlook for 2026. The company still seems a viable buy, meeting an 80-plus relative strength benchmark even after hitting a new 12-month high. However, the
Avidity Biosciences $12 billion deal saw a slip in Novartis shares, with projections showing potential overvaluation.
Generics have been reported to dent blockbuster heart drugs. Despite this, Novartis was upgraded by Morgan Stanley on stock pullback and Rhapsido launch. Furthermore, long-term
investment propensity remains strong, with Moody Lynn & Lieberson LLC acquiring over 16,000 shares of Novartis. The company has also invested over $1.7 billion in an AI allergy breakthrough, reiterating its dedication to innovative solutions. However, concerns persist over Novartis being overvalued according to Goldman Sachs, highlighting the contrast in opinions regarding the company’s stock value. Lastly, the company completed the acquisition of Regulus therapeutics, highlighting its strategic move towards
expanding and diversifying its product portfolio.
Novartis Stocks News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 17 Jan 2026 17:49:35 GMT -
Rating 4
- Innovation 3
- Information 7
- Rumor -3
